Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
about
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesEpidemiology and clinical management of tuberculosis in children in CanadaUpdates on the risk factors for latent tuberculosis reactivation and their managementsThe ongoing challenge of latent tuberculosisOne-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort StudyTumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death.Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries.Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Rationale of using different biological therapies in rheumatoid arthritis.Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitorTreatment of ankylosing spondylitis with TNF blockers: a meta-analysis.Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report.Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Diagnosis and treatment of latent tuberculosis infection.[How do register data support clinical decision-making?].Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.A patient with urinary tract tuberculosis during treatment with etanerceptDifferent Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in TaiwanSafety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research.Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline--a longitudinal analysis after using TNFa blockersTNFalpha blockade in human diseases: an overview of efficacy and safety.TNFalpha blockade in human diseases: mechanisms and future directions.Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesPatients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide.Clinical and immunologic features of an atypical intracranial mycobacterium avium complex (MAC) infection compared with those of pulmonary MAC infectionsTuberculosis subunit vaccines: from basic science to clinical testing.Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology.Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Infliximab in the treatment of rheumatoid arthritisLong-term use of adalimumab in the treatment of rheumatic diseases.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists.Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.
P2860
Q26991673-0AA4A3B8-E3DD-4A60-97FB-AD7A00B2DD24Q27027830-31640B8D-1B70-4DFD-844E-22F957B48464Q28073158-66A09659-4EA2-42F4-ACBE-FB60AF9BC41BQ28386135-85E32EB6-671D-448E-B085-F922CD150647Q28553438-DE6EE4E2-D2D8-4313-9C5E-49FFB571DEEBQ30502462-A785178E-2582-40C6-B078-E3FF7053E687Q30799235-0BCCAF53-493A-4714-8625-714012A787E5Q30891297-578EB0AE-41B3-4C28-AE2C-B6B2AB2B7D55Q33939033-FBD6C4DA-94F1-4E9C-AC38-B929FC3C5366Q34081925-6E1F4F43-AC8E-480C-A547-70D67AB75C14Q34153073-E7C64F98-BF80-48C9-AAA6-723C82B0D524Q34338355-F8BC4B42-A47E-46E5-8BF8-36114FE67A89Q34709566-A483EB0E-F145-4EC4-854A-9B3DBB4D7829Q34728162-20CCB120-308E-4702-8AAC-191A98AB8254Q34986307-DA16CD67-79CE-4A4D-9D75-5824D259FEA7Q35188551-13A14E1E-D365-4B9C-9F5E-DF61B52231F8Q35237588-F6A46BC9-F4E1-41F1-AD5E-D45F4DB9E6FFQ35307280-3D2FF25C-273A-464C-BC26-3F4C36DBA244Q35585867-76AA3187-8BB1-41B4-BC5A-1543AEEAC43AQ35705082-AD76B1A1-F4BF-4DF1-8577-D3D8F64A77BFQ35743054-8F9E248F-2248-478B-AF68-5007F313D560Q35985497-84A080BD-9BED-430A-88D8-6A7F9EEC6321Q35996265-EEB949E6-E0A2-4CFD-B72B-EBBF29469AD5Q36176854-F3AAB14B-865C-4038-9CB6-9BEB9B712DC4Q36321468-5C29EA23-B967-4FF6-AE06-A729F63F32F1Q36536861-75715CF2-6951-4FA7-9142-F03EACE5085FQ36536886-12703341-9DBA-47B0-8246-9BB8582E3F7CQ36700127-72E97C64-1F6D-4A5B-BC6F-49F9020FCF85Q36724093-BEB373A8-AF31-471C-9276-8FB2288BA699Q36753933-A3772EBA-A27E-40E1-9C4B-71B2A78D95D4Q36933047-7669C1C1-D11D-48A1-AB24-8C065FB734A6Q36960497-34AAB140-E416-40C2-9D4F-8A997AE66B9BQ37021677-FA128714-8BFA-49C5-92EA-EA88EF158043Q37189376-D5D504F6-B501-4CBF-BFB6-B804DA6D5A1FQ37223169-F28BCA77-3D7E-4424-AAF0-B684CC4FBDEBQ37303230-EFECAB66-8469-48CF-AA73-9835A9B7080CQ37358124-D212582C-364E-404C-8B13-060D90BBFA28Q37358271-FE520C35-9EA0-442A-847B-B5CF0EDB56FAQ37714705-6360BC70-7D4E-45F0-A25B-E80724B9DC0BQ37729543-2721B08D-72FC-4768-A1BB-16189CA9E1A6
P2860
Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Risk of tuberculosis in patien ...... ctivation of latent infection.
@en
Risk of tuberculosis in patien ...... ctivation of latent infection.
@nl
type
label
Risk of tuberculosis in patien ...... ctivation of latent infection.
@en
Risk of tuberculosis in patien ...... ctivation of latent infection.
@nl
prefLabel
Risk of tuberculosis in patien ...... ctivation of latent infection.
@en
Risk of tuberculosis in patien ...... ctivation of latent infection.
@nl
P2093
P2860
P356
P1476
Risk of tuberculosis in patien ...... ctivation of latent infection.
@en
P2093
Biobadaser Group
Juan J Gómez-Reino
Miguel Angel Descalzo
P2860
P304
P356
10.1002/ART.22768
P577
2007-06-01T00:00:00Z